Testosterone replacement therapy faces FDA scrutiny

JAMA - Journal of the American Medical Association

Volumn 313, Issue 6, 2015, Pages 563-564

  Garnick, Marc B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; TESTOSTERONE;

ANDROGEN DEFICIENCY; BONE DENSITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; FOOD AND DRUG ADMINISTRATION; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LIBIDO; NOTE; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; TESTOSTERONE REPLACEMENT THERAPY; ADULT; ADVISORY COMMITTEE; AGED; BLOOD; CHEMICALLY INDUCED; DRUG APPROVAL; DRUG LABELING; MALE; MIDDLE AGED; UNITED STATES;

ADULT; ADVISORY COMMITTEES; AGED; CARDIOVASCULAR DISEASES; DRUG APPROVAL; DRUG LABELING; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; TESTOSTERONE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84922569035     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.17334     Document Type: Note

References (10)

1. US Food and Drug Administration. 2014 Meeting materials of the Bone, Reproductive, and Urologic Drugs Advisory Committee. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/ucm404895.htm. Accessed November 20, 2014.
2. Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829-1836.
3. FinkleWD, Greenland S, Ridgeway GK, et al. Increased risk of nonfatalmyocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9(1);e85805.
4. Mohamoud MA, Chai G, Staffa J. Drug use review. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM412536.pdf. Accessed December 8, 2014.
5. Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med. 2013;173(15):1465-1466.
6. Hirsch MS, Nguyen CP, Joffe HV. Testosterone replacement therapy. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM412536.pdf. Accessed December 8, 2014.
7. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes. J Clin Endocrinol Metab. 2010;95(6):2536-2559.
8. Blazer DG, Barrett-Connor E, Brody BA, et al. Testosterone and aging:clinical research directions. http://www.iom.edu/-/media/Files/Report%20Files/2003/Testosterone-and-Aging-Clinical-Research-Directions/testosteroneonepagerFINAL.pdf. Accessed December 9, 2014.
9. Bhatt K, Johnson J. Summaryminutes of the joint meeting of the Bone, Reproductive, and Urologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM418144.pdf. Accessed December 8, 2014.
10. American Urological Association. AUA position statement on testosterone therapy. http://www.auanet.org/about/testosterone-therapy.cfm. Accessed December 2, 2014.